Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC Study

Grant D Stewart; Leander Van Neste; Philippe Delvenne; Paul Delrée; Agnès Delga; S Alan McNeill; Marie O'Donnell; James Clark; Wim Van Criekinge; Joseph Bigley; David J Harrison

doi:10.1016/j.juro.2012.08.219

Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC Study

Grant D Stewart, Leander Van Neste, Philippe Delvenne, Paul Delrée, Agnès Delga, S Alan McNeill, Marie O'Donnell, James Clark, Wim Van Criekinge, Joseph Bigley, David J Harrison

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Concern about possible false-negative prostate biopsy histopathology findings often leads to rebiopsy. A quantitative methylation specific polymerase chain reaction assay panel, including GSTP1, APC and RASSF1, could increase the sensitivity of detecting cancer over that of pathological review alone, leading to a high negative predictive value and a decrease in unnecessary repeat biopsies.

Original language	English
Pages (from-to)	1110-1116
Number of pages	7
Journal	The Journal of Urology
Volume	189
Issue number	3
DOIs	https://doi.org/10.1016/j.juro.2012.08.219
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Prostate
Prostatic neoplasms
Biopsy
Epigenomics
Urology

Access to Document

10.1016/j.juro.2012.08.219

Handle.net

Persistent link

Cite this

Stewart, G. D., Van Neste, L., Delvenne, P., Delrée, P., Delga, A., McNeill, S. A., O'Donnell, M., Clark, J., Van Criekinge, W., Bigley, J., & Harrison, D. J. (2013). Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC Study. The Journal of Urology, 189(3), 1110-1116. https://doi.org/10.1016/j.juro.2012.08.219

@article{bff4c4ce9484464db0f879daab65da5a,

title = "Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC Study",

abstract = "Concern about possible false-negative prostate biopsy histopathology findings often leads to rebiopsy. A quantitative methylation specific polymerase chain reaction assay panel, including GSTP1, APC and RASSF1, could increase the sensitivity of detecting cancer over that of pathological review alone, leading to a high negative predictive value and a decrease in unnecessary repeat biopsies.",

keywords = "Prostate, Prostatic neoplasms, Biopsy, Epigenomics, Urology",

author = "Stewart, \{Grant D\} and \{Van Neste\}, Leander and Philippe Delvenne and Paul Delr{\'e}e and Agn{\`e}s Delga and McNeill, \{S Alan\} and Marie O'Donnell and James Clark and \{Van Criekinge\}, Wim and Joseph Bigley and Harrison, \{David J\}",

note = "M1 - Article",

year = "2013",

doi = "10.1016/j.juro.2012.08.219",

language = "English",

volume = "189",

pages = "1110--1116",

journal = "The Journal of Urology",

issn = "1527-3792",

publisher = "Wolters Kluwer Health",

number = "3",

}

Stewart, GD, Van Neste, L, Delvenne, P, Delrée, P, Delga, A, McNeill, SA, O'Donnell, M, Clark, J, Van Criekinge, W, Bigley, J & Harrison, DJ 2013, 'Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC Study', The Journal of Urology, vol. 189, no. 3, pp. 1110-1116. https://doi.org/10.1016/j.juro.2012.08.219

TY - JOUR

T1 - Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies

T2 - results of the MATLOC Study

AU - Stewart, Grant D

AU - Van Neste, Leander

AU - Delvenne, Philippe

AU - Delrée, Paul

AU - Delga, Agnès

AU - McNeill, S Alan

AU - O'Donnell, Marie

AU - Clark, James

AU - Van Criekinge, Wim

AU - Bigley, Joseph

AU - Harrison, David J

N1 - M1 - Article

PY - 2013

Y1 - 2013

N2 - Concern about possible false-negative prostate biopsy histopathology findings often leads to rebiopsy. A quantitative methylation specific polymerase chain reaction assay panel, including GSTP1, APC and RASSF1, could increase the sensitivity of detecting cancer over that of pathological review alone, leading to a high negative predictive value and a decrease in unnecessary repeat biopsies.

AB - Concern about possible false-negative prostate biopsy histopathology findings often leads to rebiopsy. A quantitative methylation specific polymerase chain reaction assay panel, including GSTP1, APC and RASSF1, could increase the sensitivity of detecting cancer over that of pathological review alone, leading to a high negative predictive value and a decrease in unnecessary repeat biopsies.

KW - Prostate

KW - Prostatic neoplasms

KW - Biopsy

KW - Epigenomics

KW - Urology

UR - https://www.scopus.com/pages/publications/84873722466

U2 - 10.1016/j.juro.2012.08.219

DO - 10.1016/j.juro.2012.08.219

M3 - Article

SN - 1527-3792

VL - 189

SP - 1110

EP - 1116

JO - The Journal of Urology

JF - The Journal of Urology

IS - 3

ER -

Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC Study

Abstract

UN SDGs

Keywords

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this